Articles tagged with Cancer Medication
Researchers discovered that griseofulvin inhibits cancer cell growth by affecting mitosis, potentially providing a therapeutic advantage when combined with other treatments. The drug has been used for decades to treat fungal infections and shows mild anti-cancer activity.
Researchers found that Gleevec, a cancer drug, slowed the spread of poxviruses in mice. The study suggests that Gleevec might be useful as a preventative against adverse effects of smallpox vaccine.
A two-year project at the University of Edinburgh aims to understand the cultural practices and needs of Sikh and Muslim patients nearing the end of life. The study will explore how caregivers can better support these communities, highlighting the importance of transcultural training for healthcare professionals.
Researchers at USF have discovered a tailored therapy for tumors with high levels of active Akt, which is abundant in 40% of women with ovarian cancer. The compound tricirbine has been found to inhibit some cancers and will be tested in clinical trials starting within six to eight months.
Research reveals that an individual's genetic makeup determines how arsenic is metabolized, affecting disease risk. The study found a specific gene variant associated with altered urinary arsenic metabolites in children, but not adults.
Scientists at Sanford Burnham Prebys Institute have identified three lead compounds that inhibit anthrax lethal factor (LF) with high potency and selectivity. The compounds, when combined with antibiotics like Ciprofloxacin, showed a two-fold increase in survival rate for mice infected with anthrax spores.
Researchers developed mathematical model to estimate probability of drug-resistant mutant cells and identify optimal combination of three drugs. The model suggests a 'cocktail' approach is needed to reduce treatment failure rates, improving outcomes for patients with CML.
Researchers have made advances in nuclear medicine, providing alternatives to traditional chemotherapy treatment for non-Hodgkin's lymphoma patients. The new treatments showed improved response rates and durations, exceeding those following chemotherapy, and offer a personalized dose option.
David M. Goldenberg, a pioneer in radiolabeled antibodies, has received the Society of Nuclear Medicine's 2005 Paul C. Aebersold Award. He has developed antibodies for various cancer types and therapies, making significant contributions to nuclear medicine.
The Burnham Institute will screen 2 million compounds against 20 disease targets per year, revealing specific compounds that interact with and inhibit disease-causing proteins. The new capabilities will accelerate the discovery of novel medicines for various diseases.
Fine-tuning drug levels in neuroblastoma patients can improve treatment outcomes, according to St. Jude researchers. By closely monitoring and adjusting topotecan levels, the study demonstrates that pharmacokinetic-based dosing can tailor cancer treatment to individual children, potentially increasing long-term survival rates.
Researchers at UNC Chapel Hill found that radiation exposure at older ages significantly increases the risk of lung cancer among Hanford nuclear workers. The study analyzed data from 26,389 workers hired between 1944 and 1978 and identified 2,265 cancer deaths.
Researchers at Michigan Medicine have developed a nanoparticle-based treatment that targets cancer cells, increasing therapeutic response and reducing drug toxicity. The treatment uses dendrimers to deliver methotrexate and folate, allowing the cancer cells to internalize the drugs while minimizing harm to normal cells.
A novel technique developed by Stanford researchers allows scientists to distinguish between possible cancer-causing genes and those that are harmless. Mutations in the PI3K gene were found to be a primary driver of melanoma, while a mutation in the B-Raf gene did not cause cancer despite being commonly associated with the disease.
A 14-month study found that dexmethyphenidate (d-MPH) significantly reduced fatigue and improved memory in cancer survivors with chemobrain. The medication, taken at dosages of 10-50 mg per day, showed safe and effective results for relieving chemobrain symptoms.
A recent analysis found that U.S. adults could save up to $8.8 billion per year by using generic drugs instead of brand-name drugs. Additionally, a study on Gulf War veterans revealed four more common health conditions among those who served in the conflict compared to non-deployed individuals.
A study found that a life-long deficiency of insulin-like growth factor-1 (IGF-1) decreased cancer risk by approximately 45 percent and decreased cancer deaths by 12-15 percent. Low-calorie diets may also reduce IGF-1 levels, potentially reducing cancer risk.
Researchers are exploring marine natural products as a source of new medicines, including compounds that target cancer cells and regulate calcium flow. One compound, phorboxazole, has shown potential in inhibiting tumor cell growth at low concentrations.
A study published in PNAS found that prenatal exposure to diethylstilbestrol (DES) can permanently alter tissue in rats, making them more susceptible to hormone-dependent tumors. The researchers believe this phenomenon could explain why some people with inherited tumor suppressor gene defects develop cancer while others do not.
A new study found that long-term daily use of aspirin was associated with an increased risk of ER/PR-negative breast cancer, while long-term daily use of ibuprofen was linked to a higher risk of nonlocalized breast cancer. Regular NSAID use was not associated with breast cancer risk.
A new study found that statin use can decrease the risk of colon cancer in people taking cholesterol-lowering medications. Researchers analyzed data from over 1,900 participants and found a 47% reduced risk of colorectal cancer among those taking statins.
Pediatric oncologist Peter C. Adamson emphasizes the need for targeted treatments that spare healthy cells, reducing toxic side effects. The Institute of Medicine report proposes a public-private partnership to develop new pediatric anticancer drugs.
Scientists at UCSB have discovered a protein called vacuolar ATPase that naturally prevents inappropriate cell fusion, which can lead to cancer metastasis. This finding may pave the way for new treatments to enhance organ regeneration by stem cells, prevent cancer progression, and control fertility.
A new polysaccharide, hyaluronan oligomers, has been discovered to sensitize drug-resistant breast cancer cells to several chemotherapeutic drugs by binding to CD44 receptor. Increasing hyaluronan synthesis in cells also increases resistance to drug treatment.
Researchers found that dutasteride suppresses blood flow in benign prostate tissue, enabling targeted biopsies to detect cancer more effectively. This reduction in benign blood flow improved cancer detection rates and may reduce the need for repeat biopsies.
Researchers at UNC Health Care System have developed a new continuous-infusion method for administering busulfan, which achieved more predictable levels of the drug in patients. The new method has the potential to increase treatment effectiveness while avoiding side effects by maintaining consistent drug levels.
A new protein targets tumor vasculature by inducing coagulation when administered systemically, delaying tumor growth and producing some tumor regressions. The treatment shows promise for cancer therapy, adding a powerful punch to the fight against cancer.
Researchers studied the combination of S-1, a new drug, and cisplatin in patients with advanced gastric cancer. Overall, 65% of patients responded to the chemotherapy, showing tumors shrunk in response to the drug.
Researchers found that most imaging scans are unnecessary and can be avoided by confirming medication delivery within 24 hours of indium 111-labeled Zevalin injection. This simplifies treatment and improves patient compliance.
A study found that cetuximab, an Erbitux-based treatment, helped shrink tumors and extend survival in patients with metastatic colorectal cancer who had previously failed treatment. The typical patient survived 6.6 months after treatment.
A study at the American Society of Clinical Oncology meeting found that a targeted cancer drug combined with low-dose chemotherapy shrinks ovarian cancer tumors in nearly half of patients. The treatment also slows disease progression and achieves stable disease in 59% of patients.
Researchers found that blocking the Odc gene with the drug DFMO prevents cancer development in laboratory models, including lymphoma. The study suggests that a similar approach might prevent or slow cancer development in other types of cancer.
Researchers have identified a chaperone protein called HSP90 as the key player in green tea's protective effects against cancer. By understanding this mechanism, scientists hope to develop more potent anti-cancer compounds.
A study by the University of California - Davis Health has demonstrated a significantly improved survival rate for locally advanced lung cancer patients using a chemotherapy regimen that includes docetaxel. The study showed a five-year survival rate of 29 percent, surpassing previous results.
Researchers discovered an antibody compound that effectively targets and destroys blood vessels within cancerous tumors, reducing tumor growth by 93% when combined with docetaxel. This promising treatment approach may offer a new solution to treating breast cancer patients with limited effectiveness from traditional therapies.
A phase II clinical trial evaluated SU11248 for carcinoid and pancreatic islet cell tumors, demonstrating 80% stabilization of disease progression. The drug hinders key proteins and receptors that cancer cells rely on to thrive.
Researchers found no improvement in hot flash symptoms when women took black cohosh compared to placebo. In contrast, a progestational agent reduced hot flashes by up to 90% and improved sleep quality, with benefits lasting at least six months.
A phase II trial found that Herceptin can be used safely for bladder cancer with few serious adverse effects related to the drug. The study showed good responses to treatment in patients with HER2-positive bladder cancer, laying the foundation for a future phase III trial.
A new kidney cancer drug has shown a partial response rate of 40% in patients with metastatic renal cell carcinoma, significantly higher than the standard treatment's 15% response rate. The medication, SU11248, was well-tolerated and had significant side effects, but offered improved survival rates for some patients.
Researchers at Vanderbilt University Medical Center found that adding bevacizumab to standard chemotherapy extended median survival by 2.3 months, improving overall tumor response rates and progression-free survival. This new treatment regimen is recommended as the standard for advanced non-small cell lung cancer patients.
Researchers have discovered a new way to selectively block estrogen's effects using the Tamoxifen-like drug GW5638. This breakthrough could lead to more effective treatments for breast cancer and other estrogen-related diseases without increasing the risk of endometrial cancer.
A Massey Cancer Center researcher has identified the atomic structure of angiopoietin-2, a key protein involved in the neo-vascularization of solid tumors. This discovery may lead to better exploration of how to turn off cancer growth signals and identify potential therapeutics.
A combination of chemotherapy drugs showed improved overall and progression-free survival rates compared to a single drug, gemcitabine. Patients treated with the combination regimen (PEGF) had a higher percentage alive without disease after 4 months than those on standard treatment.
Researchers found that advanced NSCLC patients with high EGFR gene copy number, protein expression, or mutations respond better to gefitinib. High EGFR gene copy number is associated with prolonged survival and disease control.
The Research on Adverse Drug Events and Reports (RADAR) Project has identified serious adverse drug reactions with 14 commonly prescribed drugs and cardiac stents, affecting almost 1,700 patients. RADAR reviews have been published in leading medical journals and have helped save hundreds to thousands of patient lives.
The FDA approved clofarabine for pediatric patients with relapsed or refractory ALL, built on years of effective use of pre-1980 drugs and adaptable for adult use later. Researchers say this approval is crucial for giving children access to new anti-cancer drugs.
A study by Vanderbilt University researchers found that inhibiting COX-1 slowed the growth of epithelial ovarian tumors in a mouse model. This breakthrough suggests targeting COX-1 as a novel approach to prevent and treat ovarian cancer.
A new study found that slow recovery of normal white blood cells and high levels of leukaemic cells are predictive of relapse. The researchers discovered that these two factors predict outcome by distinct mechanisms, offering potential for personalized therapy adjustment.
A study found that commercially available extracts of black cohosh increased cell killing by two of four drugs used in cancer therapy for breast cancer patients. However, the herb also decreased the effectiveness of one drug. Further research is needed to understand why these effects occur.
RAD001 targets mTOR enzyme in high-AKT activity ovarian cancer cells, arresting cell division and reducing angiogenesis. The treatment may be combined with chemotherapy to kill weakened cancer cells.
The HER-2 gene has been found to play a major role in prostate cancer recurrence, according to a new study published in Cancer Research. Inhibiting the HER-2 protein may provide a novel treatment strategy for targeting advanced prostate cancer.
Researchers have reported encouraging results with the novel drug AMN107, which is showing an increasingly strong benefit as doses are raised. Over 90% of patients with earlier stage Chronic Myeloid Leukemia (CML) have achieved a hematologic response, and over 70% of those in advanced stages have also benefited.
Research reveals that the compound damages DNA by targeting two enzymes: thymidylate synthase and topoisomerase. This understanding could enable combination therapies for greater effectiveness and better patient outcomes. The compound has been shown to be 300-400 times more effective than fluorouracil at killing cancer cells.
Scientists have developed a new compound, AMN107, that shows promise in overcoming resistance to Gleevec, a highly successful leukemia treatment. In studies, AMN107 was found to be at least 20 times more potent than Gleevec against most resistant mutants, offering a potential cure for patients with acquired drug resistance.
The study found that sulindac induced expression of the p21 gene, which suppressed tumor formation even in mice missing key tumor suppressor genes and fed a high-fat diet. The researchers suggest that p21 activation through sulindac offers protection against both genetic and dietary factors contributing to cancer development.
Penn researchers have determined the structure of Erbitux's binding site to cancer cells, providing new insight into how it blocks cell growth-promoting activities. This finding will steer future treatment design for colon-cancer medications and potentially lead to easier delivery methods.
A recent study published by Johns Hopkins Medicine suggests that statin use may lower the risk of developing advanced prostate cancer by half. The researchers tracked 34,438 male health professionals and found that those taking cholesterol-lowering drugs had a significantly reduced risk of advanced prostate cancers.
Happiness has been found to be related to the functioning of key body processes, including lower cortisol levels and healthier cardiovascular systems. Researchers also discovered a Chinese herbal medicine component that can inhibit cancer cell growth.
A low-dose blend of celecoxib and Lipitor significantly reduces invasive and non-invasive colon adenocarcinomas by 95% in laboratory animals. The combination targets different molecular pathways to prevent colon cancer development, suggesting a promising approach for maximizing anti-cancer efficacy while minimizing toxicity.
Researchers developed a test to measure CDK activity, which accurately predicts tumor response to Tarceva. A second study found that increased CDK activity correlates with sensitivity to Taxol, providing preclinical evidence for developing a novel device to measure CDK activity in human tissue.